Who Paid My Doc Search
Menu
Organisation paid for research Program year 2024 Source: CMS Open Payments

Behavioral Research Specialists

Neither a doctor nor a teaching hospital

Research payments

$2,282,298

212 payments

Through program year 2024, Behavioral Research Specialists is reported as receiving $2,282,298 in research payments, across 212 payments.

By program year

6 rows
Year Kind Amount Payments
2024 Research $14,618 4
2023 Research $623,377 13
2022 Research $436,386 15
2021 Research $395,515 46
2020 Research $327,285 67
2019 Research $485,117 67

Breakdown

Who paid Research payments · program years 2019–2024
  1. Janssen Research & Development, LLC $1,493,079 62 payments
  2. Allergan Inc. $417,403 72 payments
  3. Teva Pharmaceuticals USA, Inc. $326,701 51 payments
  4. ACADIA Pharmaceuticals Inc $18,595 5 payments
  5. Eisai Inc. $10,336 4 payments
  6. Boehringer Ingelheim Pharma GmbH & Co.KG $8,979 3 payments
  7. Boehringer Ingelheim Pharmaceuticals, Inc. $3,985 3 payments
  8. Boehringer Ingelheim RCV GmbH & Co KG $3,220 12 payments
Studies the money was for Research payments · program years 2019–2024
  1. A Study of Esketamine Nasal Spray Administered as Monotherapy in Adult Participants With Treatment resistant Depression $1,288,358 36 payments
  2. A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Risperidone Extended-Release Injectable Suspension (TV-46000) for Subcutaneous Use as Maintenance Treatment in Adult and Adolescent Patients With Schizophrenia $317,425 44 payments
  3. A Double-Blind, Placebo-Controlled Study of Cariprazine As Adjunctive Therapy in Major Depressive Disorder $200,706 20 payments
  4. An Open-label Long-term Extension Safety Study of Intranasal Esketamine in Treatment-resistant Depression $184,900 24 payments
  5. A Double-Blind, Placebo-Controlled, Randomized Withdrawal, Multicenter Clinical Trial Evaluating the Efficacy, Safety, and Tolerability of Cariprazine in A Dose-Reduction Paradigm in the Prevention of Relapse in Bipolar I Disorder Patients Whose Current $74,484 17 payments
  6. A Double-Blind, Placebo-Controlled, Randomized Withdrawal,Multicenter Clinical Trial Evaluating the Efficacy, Safety, and Tolerability of Cariprazine in A Dose-Reduction Paradigm in the Prevention of Relapse in Patients With Schizophrenia $38,689 6 payments
  7. A Randomized, Double-blind, Placebo-controlled, Multicenter, Efficacy and Safety Study of Rapastinel for Rapid Treatment of Symptoms of Depression and Suicidality in Adult Patients with Major Depressive Disorder $38,003 11 payments
  8. A Double-Blind, Placebo-Controlled Study of Cariprazine As Adjunctive Therapy in Major Depressive Disorder $35,107 5 payments
  9. An Open label Long term Extension Safety Study of Intranasal Esketamine in Treatment resistant Depression $19,821 2 payments
  10. Acp-103-055 $17,409 4 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2024

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record